Creatine for Depression, Mood, and Mental Fatigue

This article is for general educational purposes only. It is not medical advice and should not replace consultation with a qualified healthcare provider. If you have symptoms or concerns about your supplement use, speak with a doctor or registered dietitian before making changes.

Creatine is one of the most studied sports supplements on the market, but a quieter body of research has been accumulating on something most users don't expect: its relationship with mood and depression, which has been explored in research. The data is interesting, the proposed mechanisms are biologically plausible, and the evidence base is also weaker than enthusiasts tend to acknowledge.

Why the Brain Cares About Creatine

The brain is a high-energy organ. Neurons rely heavily on ATP to maintain membrane potential, power ion pumps, and sustain neurotransmitter synthesis. The phosphocreatine system — the same one that buffers ATP during intense muscle contractions — is also active in brain tissue, particularly in regions with high metabolic demand.

A 2022 review in Nutrients summarizes the current state: creatine supplementation may elevate brain creatine content in humans, and preliminary data suggest possible effects on symptoms of concussion, sleep deprivation, and depression, though the evidence is described as early-stage and the authors note that effects on neurodegenerative disease appear limited.

A second mechanism — less commonly discussed but perhaps more compelling — involves the methylation pathway. Creatine synthesis is one of the largest consumers of methyl groups in the body, accounting for an estimated 40–50% of the body's daily methylation demand. When supplemental creatine reduces the need for endogenous production, the argument goes that freed-up methyl donors may be redirected toward other methylation-dependent processes — including neurotransmitter synthesis (serotonin, dopamine, norepinephrine) through the BH4 cycle. This is a proposed mechanistic pathway, not a confirmed one, and it has not been demonstrated in clinical outcomes. Individual genetic variation in methylation enzymes (MTHFR, COMT, and others) likely affects individual responses, though this remains poorly characterized in research.

What the Clinical Research Shows

A 2025 meta-analysis in the British Journal of Nutrition is the most comprehensive synthesis to date. Eleven randomized trials covering 1,093 participants found a standardized mean difference of −0.34 for depressive symptoms — equivalent to roughly 2.2 points on the 17-item Hamilton Depression Rating Scale. That figure falls below the accepted minimal clinically important difference of 3.0 points. The GRADE certainty of evidence was rated very low, and the authors note substantial heterogeneity (I² = 71.3%) as well as signs of bias favoring creatine. Their conclusion: some analyses have reported small effect sizes, though the certainty of evidence is very low, results are inconsistent, and the true effect may be trivial or null. Larger trials are needed.

A separate 2025 pilot RCT published in European Neuropsychopharmacology tested creatine as an adjunct to cognitive-behavioral therapy in 100 participants with depression. At eight weeks, PHQ-9 scores were significantly lower in the creatine-plus-CBT group compared to placebo-plus-CBT (mean difference −5.12 points). This was described as hypothesis-generating; the authors called for larger, longer trials before drawing clinical conclusions.

The 2022 WFSBP/CANMAT guidelines — which synthesize Grade A evidence across nutraceuticals — rated creatine "+/-" (Not Currently Recommended) as monotherapy for unipolar depression, reflecting mixed and insufficient evidence. This represents a conservative interpretation of the current evidence.

The Women and Perimenopause Angle

One area where the early data is more specific involves women. Several researchers have noted that women have lower baseline creatine stores than men, which may make them more responsive to supplementation. A 2026 RCT in the Journal of the American Nutrition Association found that medium-dose creatine hydrochloride supplementation over eight weeks increased frontal brain creatine levels, improved reaction time, and reported a non-significant trend toward changes in mood measures in perimenopausal and menopausal women compared to placebo (p = 0.06).

Anecdotal reports describing subjective changes exist in supplement communities, though these are not reliable evidence and are not reflected in controlled trial timelines.

Who Reports Negative Effects

Not everyone responds positively. Some users — particularly those where individual metabolic differences have been proposed to play a role — report that creatine worsens sleep, increases anxiety, or causes an energy crash. The proposed explanation connects back to methylation: a connection to methylation throughput has been hypothesized in anecdotal discussions, though it is not well characterized in clinical research. A rebound effect from stopping creatine has similarly been described in anecdotal reports, but has not been established in controlled studies.

These reports are anecdotal and poorly characterized in the literature. Individual responses vary, and whether anyone experiences this effect is not reliably predictable without understanding their specific metabolic and genetic context. This is not something to reason through independently — it is worth discussing with a healthcare provider if you notice unexpected mood or sleep changes with creatine use.

What Published Reference Ranges Describe

This section describes general information from published research. It is not a dosing recommendation. Talk to a healthcare provider before changing your supplement routine.

Trials studying creatine for brain and mood outcomes have most commonly administered 3–5 grams daily in controlled research settings — the same range used in athletic performance research. Studies specifically focused on cognition tend to cluster in this range. A 2018 systematic review in Experimental Gerontology found evidence that short-term memory and intelligence/reasoning may be improved by creatine in healthy individuals, with vegetarians showing a larger response — likely because they have lower baseline tissue levels from diet.

Higher amounts (10 grams and above) are discussed in some community contexts for maximizing cognitive effects, but this is not supported by systematic clinical evidence and falls outside most published study protocols.

What is described in the literature as a studied dose is not a recommendation for any individual. Speak with a healthcare provider before adjusting your supplement routine.

The Hype Problem

A 2025 commentary in The Journal of Nutrition examined the growing disconnect between commercial enthusiasm for creatine as a cognitive enhancer and the actual state of the evidence. The authors argue that cognitive biases and structural incentives in the supplement industry have contributed to a narrative that the data cannot yet support. The review does not dismiss creatine's potential — it argues for greater critical appraisal and transparency in how health claims are communicated.

That framing is useful here. Creatine has a genuinely interesting mechanistic case and a growing (if limited and uncertain) clinical evidence base for mood and cognitive effects. It is not a proven antidepressant. If you are experiencing symptoms of depression, this is a conversation to have with a clinician — not something to manage independently based on supplement research.

---

Related compounds: creatine · magnesium · methylfolate